🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with estimates suggesting over 82 million instances per year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs currently available.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, alternatively called a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, was also approved in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Results and Global Access

According to data published in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The study enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in many developing nations.

Doctors treating patients have expressed positive views. Having a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea worldwide.